

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1952)**

## **REMOVAL OF STOCK MARKER “B”**

Reference is made to the announcement of Everest Medicines Limited (the “**Company**”) dated 22 April 2025 (the “**Announcement**”) with respect to the approval granted by the Stock Exchange for the dis-application of Rules 18A.09 to 18A.11 of the Listing Rules to the Company. Unless otherwise defined, capitalised terms herein shall have the same meanings as those defined in the Announcement.

Further to the Announcement, the Company wishes to advise shareholders and potential investors that the “B” marker will cease to be affixed to the Company’s English and Chinese stock short name from 2 May 2025 and the Company’s shares will be traded on the Stock Exchange under the new stock short name of “EVEREST MED” in English and “雲頂新耀” in Chinese. The stock code of the Company remains unchanged as “1952”.

By order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
*Chairman and Executive Director*

Hong Kong, 25 April 2025

*As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. William Ki Chul Cho and Mr. Honggang Feng as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.*